Consolidated Q2 FY27 revenue up 30.4 percent, profit after tax up 57.4 percent year on year
SMSPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.1 pts less than Nifty Microcap 250 and 1.3 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
For the consolidated September 2026 quarter, revenue rose 30.4 percent year on year to Rs 31,608.93 lakh, and profit after tax rose 57.4 percent to Rs 3,985.25 lakh. EBITDA margin rose to 21.4 percent from 20.0 percent. Half-year consolidated profit after tax was Rs 6,076.15 lakh; operating cash inflow was Rs 10,575.95 lakh. Auditor review was unmodified. The Company Secretary resigned for personal reasons; the successor starts November 5, 2026.
Strong revenue, profit and margin growth plus positive operating cash flow support shareholders; the Company Secretary change appears routine.
The filed figures for this quarter have not reached us in XBRL yet, so there is nothing to compute here; the read above is the AI's, from the document. The table appears the moment the figures land.